Literature DB >> 23132270

Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model.

Jing Qiao1, Hong Li, Ming Li.   

Abstract

Disruption of conditioned avoidance response (CAR) in rodents is one trademark feature of many antipsychotic drugs. In adult rats, repeated olanzapine (OLZ) treatment causes an enhanced disruption of avoidance response (sensitization), whereas repeated clozapine (CLZ) treatment causes a decreased disruption (tolerance). The present study addressed (1) whether OLZ sensitization and CLZ tolerance can be induced in adolescent rats, and (2) the extent to which OLZ sensitization and CLZ tolerance induced in adolescence persists into adulthood. Male adolescent Sprague-Dawley rats (approximate postnatal days (∼P) 43-47) were first treated with OLZ (1.0 or 2.0 mg/kg, subcutaneously (sc)) or CLZ (10 or 20 mg/kg, sc) daily for 5 consecutive days in the CAR model. They were then tested for the expression of OLZ sensitization or CLZ tolerance either in adolescence (∼P 50) or after they matured into adults (∼P 76 and 92) in a challenge test during which all rats were injected with either a lower dose of OLZ (0.5 mg/kg) or CLZ (5.0 mg/kg). When tested in adolescence, rats previously treated with OLZ showed a stronger inhibition of CAR than those previously treated with vehicle (ie, sensitization). In contrast, rats previously treated with CLZ showed a weaker inhibition of CAR than those previously treated with vehicle (ie, tolerance). When tested in adulthood, the OLZ sensitization was still detectable at both time points (∼P 76 and 92), whereas the CLZ tolerance was only detectable on ∼P 76, and only manifested in the intertrial crossing. Performance in the prepulse inhibition and fear-induced 22 kHz ultrasonic vocalizations in adulthood were not altered by adolescence drug treatment. Collectively, these findings suggest that atypical antipsychotic treatment during adolescence can induce a long-term specific alteration in antipsychotic effect that persists into adulthood despite the brain maturation. As antipsychotic drugs are being increasingly used in children and adolescents in the past two decades, findings from this study are important for understanding the impacts of adolescent antipsychotic treatment on the brain and behavioral developments. This work also has implications for clinical practice involving adolescence antipsychotic treatments in terms of drug choice, drug dose, and schedule.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23132270      PMCID: PMC3547203          DOI: 10.1038/npp.2012.213

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  55 in total

1.  Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs.

Authors:  Tao Sun; Gang Hu; Ming Li
Journal:  Eur J Pharmacol       Date:  2008-11-27       Impact factor: 4.432

Review 2.  Developmental trajectories during adolescence in males and females: a cross-species understanding of underlying brain changes.

Authors:  Heather C Brenhouse; Susan L Andersen
Journal:  Neurosci Biobehav Rev       Date:  2011-05-12       Impact factor: 8.989

3.  Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats.

Authors:  Andrew J Goudie; Jon C Cole; Harry R Sumnall
Journal:  Behav Pharmacol       Date:  2007-02       Impact factor: 2.293

4.  Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens.

Authors:  M H Teicher; S L Andersen; J C Hostetter
Journal:  Brain Res Dev Brain Res       Date:  1995-11-21

5.  Recovery of sensorimotor gating without G protein adaptation after repeated D2-like dopamine receptor agonist treatment in rats.

Authors:  Kerry E Culm; Ronald P Hammer
Journal:  J Pharmacol Exp Ther       Date:  2003-10-30       Impact factor: 4.030

Review 6.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

7.  Postnatal development of dopamine and serotonin transporters in rat caudate-putamen and nucleus accumbens septi.

Authors:  F I Tarazi; E C Tomasini; R J Baldessarini
Journal:  Neurosci Lett       Date:  1998-09-18       Impact factor: 3.046

8.  Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism.

Authors:  A Mead; M Li
Journal:  J Psychopharmacol       Date:  2009-03-27       Impact factor: 4.153

9.  Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.

Authors:  Urs Meyer; Erica Spoerri; Benjamin K Yee; Markus J Schwarz; Joram Feldon
Journal:  Schizophr Bull       Date:  2008-10-08       Impact factor: 9.306

10.  Antipsychotic-induced suppression of locomotion in juvenile, adolescent and adult rats.

Authors:  Jenny L Wiley
Journal:  Eur J Pharmacol       Date:  2007-09-26       Impact factor: 4.432

View more
  14 in total

1.  Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.

Authors:  Shinnyi Chou; Sean Jones; Ming Li
Journal:  Brain Res       Date:  2015-06-03       Impact factor: 3.252

2.  Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function.

Authors:  Jun Gao; Rongyin Qin; Ming Li
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

3.  Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity.

Authors:  Rongyin Qin; Yingzhu Chen; Ming Li
Journal:  Neuropharmacology       Date:  2013-08-14       Impact factor: 5.250

4.  Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

Authors:  Shinnyi Chou; Collin Davis; Sean Jones; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2014-11-26       Impact factor: 3.533

5.  Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model.

Authors:  Qing Shu; Gang Hu; Ming Li
Journal:  J Psychopharmacol       Date:  2013-11-20       Impact factor: 4.153

6.  Asenapine sensitization from adolescence to adulthood and its potential molecular basis.

Authors:  Qing Shu; Rongyin Qin; Yingzhu Chen; Gang Hu; Ming Li
Journal:  Behav Brain Res       Date:  2014-08-02       Impact factor: 3.332

7.  Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley rats: a possible D2 receptor mediated phenomenon?

Authors:  Jing Qiao; Jun Gao; Qing Shu; Qinglin Zhang; Gang Hu; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2013-12-21       Impact factor: 4.530

8.  Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism.

Authors:  Jun Gao; Ming Li
Journal:  Behav Brain Res       Date:  2013-10-05       Impact factor: 3.332

9.  Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood.

Authors:  Jun Gao; Ming Li
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-06-03       Impact factor: 5.067

10.  Effects of central activation of serotonin 5-HT2A/2C or dopamine D 2/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test.

Authors:  Min Feng; Jun Gao; Nan Sui; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2014-10-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.